Continue to enjoy the positive fundamental progress, absence of dilution outside of Keysight which brings with it its own positive narrative.
i would have thought by this stage of the trials that a few well paid neurologists / radiologists would have seen/heard about the progress (or maybe used the device directly) and taken a punt on it - with the low shares on offer, would have expected a more than a few ‘pops’ in the share price over the recent period. Outside of the initial Keysight excitement, it’s been tough to watch.
am I right to assume some level of buzz / literal buy-in from the medical community as trials progress in a positive fashion? Or is there some kind of non-disclosure agreement in place that means I’m barking up the wrong tree?
EMvision Research Notes, page-2533
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.00 |
Change
0.020(1.01%) |
Mkt cap ! $170.4M | |||
| Open | High | Low | Value | Volume |
| $1.98 | $2.00 | $1.98 | $37.48K | 18.83K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 255 | $1.98 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.00 | 4046 | 1 |
View Market Depth
| Last trade - 16.10pm 22/07/2024 (20 minute delay) ? |
| EMV (ASX) Chart |